UHS said the carrying value of its debt was approximately $4.9 billion and the fair value was approximately $4.6 billion as of December 31, 2023, and its total debt as a percentage of total capitalization was approximately 44%. The comparable figures as of December 31, 2022 were approximately $4.8 billion for carrying value, $4.4 billion for fair value and 45% for debt to total capitalization.

1. 01

   UHS said the carrying value of its debt was approximately $4.9 billion and the fair value was approximately $4.6 billion as of December 31, 2023, and its total debt as a percentage of total capitalization was approximately 44%. The comparable figures as of December 31, 2022 were approximately $4.8 billion for carrying value, $4.4 billion for fair value and 45% for debt to total capitalization.

2. 02

   The company said the available borrowing capacity under its existing revolving credit facility was $701 million as of December 31, 2023. It said its operating cash flows, cash and cash equivalents, available commitments under existing agreements and access to the capital markets are sufficient to fund its needs for the next 12 months.

3. 03

   UHS said that in its acute care segment, hospital-based physician-related expenses, especially in emergency room care and anesthesiology, increased significantly and had a material unfavorable impact on its results of operations in 2023. The company said it implemented mitigation initiatives, but these physician-related expense increases could continue to have a material unfavorable impact for the foreseeable future.

4. 04

   UHS said net revenues of its U.K. behavioral health care facilities were approximately $761 million in 2023 and approximately $685 million in 2022. It said total assets at those facilities were approximately $1.327 billion as of December 31, 2023.

Key figures

Fiscal year ended December 31, 2023

Revenue

$14.3B

Operating income

$1.2B

Net income

$718M

EPS

$10.23

Operating cash flow

$1.3B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.